Advaxis Reports Positive Low Dose Cohort Phase II Trial of ADXS-HPV for CIN 2/3 Grant Zeng, CFA On Feb 27, 2012, Advaxis ( ADXS ) announced that it has completed the first of 3 dose cohorts in the single blind, placebo controlled Phase II dose escalation study assessing the safety and efficacy of ADXS-HPV in the treatment of cervical intraepithelial neoplasia (:CIN) 2/3. As a reminder, Advaxis initiated the multicenter, randomized, single blind, placebo-controlled, Phase II clinical trial of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (:CIN) in April 2010. The study is designed to assess the safety and efficacy of ADXS-HPV for the treatment of CIN grade 2/3, which is late stage cervical dysplasia that requires surgery to prevent invasive cancer.